Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
CareDx announces that the Centers for Medicare and Medicaid Services (CMS) has recommended continued coverage of AlloMap for heart transplant patients via local Medicare Administrative Contractors (MACs). This follows a memo acknowledging multiple studies demonstrating AlloMap's clinical utility since its initial request for a national coverage determination in 2013. AlloMap, adopted by over 90% of U.S. transplant centers and supported by ISHLT guidelines, continues to receive reimbursement, affirming its status as the standard of care in transplant medicine.
CareDx, Inc. (CDNA) announced its participation in the virtual 46th annual ASHI conference, taking place from October 19-21, 2020. The company will showcase its latest innovations for HLA laboratories, including a symposium led by Dr. Rajalingam Raja on October 20, highlighting the AlloSeq Tx17 HLA typing solution. Presentations and posters will cover various advancements in HLA typing, including hybrid capture techniques and genetic risk factors in transplantation. CareDx aims to strengthen community engagement and share updates on best practices in transplant patient care.
CareDx, Inc. (Nasdaq: CDNA) will release its third-quarter 2020 financial results on October 29, 2020, after market close. The conference call to review these results will be hosted by CEO Peter Maag and CFO Michael Bell at 1:30 PM PT. Interested parties can join the call by dialing 877-705-6003 or via webcast on CareDx's investor relations page. A replay will be available from October 29 at 4:30 PM PT until November 12, 2020. CareDx specializes in precision medicine for transplant patients.
CareDx, Inc. (CDNA) announced a preliminary revenue of approximately $53.0 million for Q3 2020, a 57% increase from $33.8 million in Q3 2019. This growth was driven by testing revenue of $45.2 million, up from $28.2 million year-over-year. Notably, around 21,800 AlloSure and AlloMap tests were conducted during the quarter. The company emphasizes its commitment to supporting transplant patients amid the pandemic and continues to invest in growth and digital solutions for enhanced patient care.
CareDx, Inc. (Nasdaq: CDNA) announced pivotal clinical data publications for AlloSure Lung, a non-invasive biomarker for acute cellular rejection (ACR) in lung transplant patients. The LARGO study, involving 69 patients, demonstrated AlloSure's effectiveness in identifying ACR without invasive procedures. Additionally, the University of Texas San Antonio published findings from a cohort of 48 patients, emphasizing the tool's value for monitoring allograft dysfunction, especially during the COVID-19 pandemic. Experts highlight AlloSure Lung as a promising advancement in transplant care.
CareDx, Inc. (Nasdaq: CDNA) announced the release of a final local coverage determination by Palmetto MolDx for AlloSure Heart, a dd-cfDNA test identifying cell injury that leads to organ rejection. Medicare reimbursement for this test follows a thorough technical assessment, highlighting its clinical utility in transplant management. This decision facilitates the launch of HeartCare, which combines AlloSure Heart with AlloMap Heart, offering a comprehensive, non-invasive solution for heart transplant patients during the COVID pandemic. This coverage enhances patient access and optimizes care management.
CareDx, Inc. (Nasdaq: CDNA) launched AlloCare, a mobile app aimed at enhancing medication adherence and health management for transplant patients. The app will debut at the AlloCare Transplant Festival on September 26, 2020, designed to foster connections within the transplant community. The festival will feature notable personalities and over 25 transplant organizations, emphasizing CareDx's commitment to improving long-term outcomes through innovative patient engagement solutions. The app is now available for download in the Apple App Store.
CareDx, Inc. (CDNA) announced its participation in the 28th International Congress of The Transplantation Society (TTS) from September 13-16, 2020. The company will showcase its AlloSure and AlloSeq cfDNA tools through four virtual symposia and six poster presentations. Expert speakers will discuss topics like risk prediction in kidney transplantation and the use of dd-cfDNA as a biomarker. CareDx aims to support continuous education for the transplant community and emphasize innovations in transplant medicine.
CareDx, Inc. (NASDAQ: CDNA), a precision medicine leader, has appointed new senior executives in key areas: Digital Services, Laboratory Operations, Business Development, and Market Access. The appointments aim to enhance operational efficiency amidst rapid growth. Notable new hires include Kashif Rathore, Ryan Phan, Sean Grant, and Danielle Scelfo, each bringing extensive experience from leading companies. CEO Peter Maag emphasizes the need for robust leadership to navigate increasing operational complexities and advance CareDx's market strategies.
CareDx, a precision medicine company, announced that its Chairman and CEO, Peter Maag, will present at the AAKP and George Washington University summit on July 16-17, 2020. The event focuses on innovations in kidney disease, particularly the role of artificial intelligence in transplant care. CareDx aims to enhance patient care through its digital tools, AiTraC and AlloCare, which address information management challenges for transplant patients. The summit highlights the global interest in improving transplant outcomes through data-driven solutions.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
